GlassScriptPhysician profile
Xylina T Gregg
NPI 1972554459
$31,014.48
in general payments reported to CMS, 2019-2025
58 companies · $3,692 in 2025
The $3,692 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,003 · 2020: $1,294 · 2021: $788 · 2022: $1,917 · 2023: $16K · 2024: $4,789 · 2025: $3,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $12K · Food and Beverage: $6,376 · Consulting Fee: $4,283 · Travel and Lodging: $1,358 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $11,896.00 |
| Food and Beverage | $6,375.84 |
| Consulting Fee | $4,282.50 |
| Travel and Lodging | $1,358.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $13,787.00 | 2023-2024 | |
| Daiichi Sankyo INC. | $4,984.38 | 2021-2025 | Enhertu, Datroway |
| Tesaro, INC. | $2,453.70 | 2019 | |
| Geron Corporation | $1,224.24 | 2025 | Rytelo |
| Innate Pharma, INC | $1,200.00 | 2020 | |
| Karyopharm Therapeutics INC. | $794.21 | 2022-2024 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $678.73 | 2019-2025 | Imfinzi, Imjudo, Enhertu |
| Incyte Corporation | $340.85 | 2023-2025 | Jakafi, Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $316.78 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $315.06 | 2019-2025 | |
| Gilead Sciences, INC. | $293.69 | 2021-2025 | Trodelvy |
| Sobi, INC | $287.59 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $268.95 | 2021-2025 | Monoferric |
| Apellis Pharmaceuticals, INC. | $230.27 | 2023 | Empaveli |
| Pfizer INC. | $224.36 | 2021-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $204.43 | 2022-2024 | |
| Intrinsiq Specialty Solutions, INC. | $197.39 | 2025 | |
| Abbvie INC. | $180.43 | 2022-2025 | |
| Janssen Biotech, INC. | $173.36 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Amgen INC. | $165.60 | 2019-2023 | Kyprolis |
| Agios Pharmaceuticals, INC. | $154.93 | 2019-2024 | Pyrukynd |
| Pharmaessentia USA Corporation | $152.13 | 2024-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $131.81 | 2021-2024 | Tavalisse, Rezlidhia |
| Genentech USA, INC. | $131.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.47 | 2019-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $118.90 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Cti Biopharma Corp. | $115.78 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $115.57 | 2022 | |
| Celgene Corporation | $95.91 | 2022-2024 | Reblozyl |
| Glaxosmithkline, LLC. | $92.61 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Stemline Therapeutics INC. | $92.00 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $91.80 | 2025 | |
| Astellas Pharma US INC | $81.22 | 2020-2024 | Xtandi, Padcev |
| Deciphera Pharmaceuticals INC. | $79.09 | 2023-2025 | Qinlock, Tgct |
| Pharmacyclics LLC, An Abbvie Company | $77.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.44 | 2024-2025 | Iclusig, Ninlaro |
| Tersera Therapeutics LLC | $65.80 | 2023-2025 | Zoladex, Xermelo |
| Seagen INC. | $59.89 | 2023 | Padcev, Adcetris, Tukysa |
| Array Biopharma INC | $58.80 | 2025 | Mektovi, Braftovi, Tukysa |
| Eisai INC. | $55.48 | 2023-2025 | |
| Emd Serono, INC. | $54.44 | 2022-2025 | Bavencio |
| Foundation Medicine, INC. | $51.42 | 2019 | |
| Genmab U.S., INC. | $51.11 | 2024 | Epkinly, Tivdak |
| Sumitomo Pharma America, INC. | $48.40 | 2025 | Orgovyx |
| Immunocore Limited | $48.12 | 2024-2025 | Kimmtrak |
| Tempus Ai, INC | $46.53 | 2024-2025 | Xt Cdx |
| Recordati_rare_diseases_inc. | $45.31 | 2023-2025 | Enjaymo, Sylvant |
| Bayer Healthcare Pharmaceuticals INC. | $37.05 | 2022-2025 | |
| Azurity Pharmaceuticals, INC. | $33.18 | 2025 | Danziten |
| Tactile Systems Technology INC | $32.63 | 2025 | Flexitouch Plus, Nimbl |
| Beigene USA, INC. | $32.04 | 2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $19.56 | 2025 | |
| Exelixis INC. | $19.52 | 2025 | Cabometyx |
| G1 Therapeutics, INC. | $16.71 | 2022 | |
| Beone Medicines USA, INC. | $16.56 | 2025 | Tevimbra |
| Myovant Sciences INC. | $13.38 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $12.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,970.82 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xylina Gregg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.